153 related articles for article (PubMed ID: 16019449)
1. Coagulopathy, following medical therapy, for carcinoma of the prostate.
Bern MM
Hematology; 2005 Feb; 10(1):65-8. PubMed ID: 16019449
[TBL] [Abstract][Full Text] [Related]
2. Coagulopathy in prostate cancer.
de la Fouchardière C; Flechon A; Droz JP
Neth J Med; 2003 Nov; 61(11):347-54. PubMed ID: 14768717
[TBL] [Abstract][Full Text] [Related]
3. Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.
Chakrapee-Sirisuk S; Amornpichetkul K; Visudhiphan S; Sangruchi T; Srimuninnimit V; Sinlarat P
J Med Assoc Thai; 2001 Oct; 84(10):1495-501. PubMed ID: 11804262
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
[TBL] [Abstract][Full Text] [Related]
5. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature.
Hyman DM; Soff GA; Kampel LJ
Oncology; 2011; 81(2):119-25. PubMed ID: 21986538
[TBL] [Abstract][Full Text] [Related]
6. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid.
Cooper DL; Sandler AB; Wilson LD; Duffy TP
Cancer; 1992 Aug; 70(3):656-8. PubMed ID: 1623480
[TBL] [Abstract][Full Text] [Related]
7. [Prostatic adenocarcinoma revealed by disseminated intravascular coagulation and fibrinolysis].
Rabii R; Salomon L; Hodznek A; Saint F; Cicco A; Chopin DK; Abbou CC
Ann Urol (Paris); 2002 Jul; 36(4):269-71. PubMed ID: 12162193
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
[TBL] [Abstract][Full Text] [Related]
9. [Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia].
Albiges L; Cottu PH; Cojean-Zelek I; Raymond F; Zerkak D; Aerts J; Ziza JM
Rev Med Interne; 2007 Mar; 28(3):176-8. PubMed ID: 17229492
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
11. [Consumption coagulopathy disclosing prostatic cancer].
Vantaux P; Schneider P; Le Coz S; Villers A
Prog Urol; 2001 Feb; 11(1):68-9. PubMed ID: 11296649
[TBL] [Abstract][Full Text] [Related]
12. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
Chime-Udeh E
Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
[No Abstract] [Full Text] [Related]
13. Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer--a case report.
Shirai K; Chaudhary UB
ScientificWorldJournal; 2007 Feb; 7():753-5. PubMed ID: 17619757
[TBL] [Abstract][Full Text] [Related]
14. [Disseminated intravascular coagulation syndrome with secondary fibrinolysis activation in prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Tyloch F; Szymański A
Pol Tyg Lek; 1996 Feb; 51(6-9):100-1. PubMed ID: 8756745
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
16. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
18. Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
Pinto F; Brescia A; Sacco E; Volpe A; Gardi M; Gulino G; Bassi P
Arch Ital Urol Androl; 2009 Dec; 81(4):212-4. PubMed ID: 20608143
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of the prostate. Treating disease that has metastasized.
Baum N; Brown P
Postgrad Med; 1990 Nov; 88(6):77-84. PubMed ID: 1700405
[TBL] [Abstract][Full Text] [Related]
20. [Disseminated intravascular coagulation syndrome (D.I.C.) and carcinoma of the prostate (author's transl)].
Becopoulos T; Kranides A; Mandalaki-Yianitsiotis T; Louizou K; Panagiotopoulou E; Dimopoulos C
J Urol (Paris); 1980; 86(6):467-70. PubMed ID: 6160184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
